Most U.S. adults across political parties favor allowing the Federal government authority to negotiate for drug prices — even after hearing the arguments against the health policy. Drug price negotiation, say by the Medicare program, is a unifying public policy in the current era of political schisms in America, based on the findings in a… Read More »
As Supernus’ top drug inches toward the patent cliff, the central nervous system-focused drugmaker has struck an M&A deal to quickly expand its portfolio of marketed medicines. In a $ 400 million buyout, Supernus is paying $ 8.10 per share to buy CNS drugmaker Adamas Pharmaceuticals. With the deal, Supernus gets rights to Gocovri, the first and only… Read More »
Centene and Humana filed separate lawsuits against Merck alleging the drugmaker’s “monopolistic scheme” delayed generic versions of its blockbuster cholesterol drug Zetia from coming to market, causing the insurers to pay higher prices for years. The suits by two of the biggest health insurers were filed in similar but separate lawsuits Wednesday in federal court in… Read More »
Breadcrumb Trail Links Health A antibacterial substance created by mating amphibians to protect fertilized eggs may help dispense medicine over time Author of the article: Shari Kulha A frog’s foam “balloon” encases fertilized eggs, securing the tadpoles’ safety for the first week of their lives. Photo by Getty Images Article content It’s not the topic… Read More »
Advertisement Continue reading the main story Supported by Continue reading the main story Cleveland Clinic and Mount Sinai Won’t Administer Aduhelm to Patients The rejection of the new Alzheimer’s drug by the two major medical centers is one of the starkest signs of concern over its approval by the F.D.A. The Cleveland Clinic, one of… Read More »
Sprout Pharmaceuticals’ female libido drug Addyi has traveled a winding path through FDA gatekeepers, multiple M&A deals, marketing restrictions and more. With a possible new safety flag, the controversial medicine could be set for even more scrutiny. In a rundown of potential new safety concerns on approved products, the FDA flagged the Addyi for possible risks of drug hypersensitivity.… Read More »